lisdexamfetamine / Generic mfg. - LARVOL DELTA

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) (clinicaltrials.gov) - P2/3 | N=60 | Active, not recruiting | Sponsor: Yale University | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Complications Associated With the Switch From Brand to Generic Lisdexamfetamine: Two Patient Cases. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal

Medication Adherence in Children and Adults Receiving Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Sweden: A Nationwide Study. (PubMed, J Atten Disord) - "The overall rates of treatment adherence are high for children and adults receiving ADHD medication in Sweden. We observed lower adherence among adolescents, which warrants further study."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: University of Minnesota | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

New P1 trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Effectiveness of Pharmacological Treatments for Adult ADHD on Psychiatric Comorbidity: A Systematic Review. (PubMed, J Clin Med) - "This systematic review evaluated the effectiveness of commonly prescribed medications for adult ADHD (methylphenidate, atomoxetine, bupropion, and lisdexamfetamine) on comorbid mood, anxiety, personality, and substance use disorders. Tricyclic antidepressants were also included in the search strategy; however, no eligible adult studies assessing imipramine or desipramine in patients with ADHD and psychiatric comorbidity were identified...While targeted improvements may occur in specific domains, the evidence base is insufficient to define optimal long-term strategies for adults with ADHD and complex comorbidity. Rigorous, longitudinal studies are needed to clarify medication effects on distinct comorbid profiles and to inform integrated treatment planning."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry

Efficacy of atomoxetine and oxybutynin in the treatment of pediatric obstructive sleep apnea, a three case report. (PubMed, Front Sleep) - "Of note, the first patient was concurrently treated with lisdexamfetamine for attention deficit hyperactivity disorder, while the second had morbid obesity under treatment with liraglutide. These cases suggest a potential role for atomoxetine and oxybutynin as alternative therapeutic options for pediatric OSA in complex scenarios where severe OSA persists despite AT and failed CPAP therapy, warranting further evaluation in large pediatric clinical trials. Nevertheless, the final case underscores that even pharmacological treatments, although seemingly straightforward to administer, may encounter adherence challenges."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Pediatrics • Psychiatry • Respiratory Diseases • Sleep Disorder

Reduction of Loss of Control Eating in Youth With Attention-Deficit/Hyperactivity Disorder Following Initiation of Stimulant Medication: A Prospective Study. (PubMed, J Clin Psychopharmacol) - "Findings provide preliminary support for a potential relationship between stimulant medication and reduced LOC-E and associated symptoms in youth with ADHD and comorbid LOC-E. Results mostly align with prior adult studies evaluating lisdexamfetamine for binge-eating disorder. Larger, controlled trials are needed to confirm these findings and investigate neurocognitive mechanisms. This study offers early evidence to inform future pharmacological approaches to treat ADHD and LOC-E in youth."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Binge Eating Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Sexual Functioning in Individuals With Attention-Deficit Hyperactivity Disorder: A Narrative Review. (PubMed, Cureus) - "Some authors emphasize the importance of neurobiological mechanisms such as "dopaminergic craving" or novelty-seeking, while others indicate that hypersexual behaviors may be treated as a form of self-regulation. Concerning pharmacotherapy, psychostimulant drugs (e.g., methylphenidate and lisdexamfetamine) and nonstimulants (e.g., atomoxetine and clonidine) demonstrate both beneficial and adverse impacts on sexual functioning, although empirical data are limited. ADHD shows a significant correlation with the occurrence of a wide spectrum of sexual disorders, which requires consideration in diagnostics and treatment planning. The high prevalence of hypersexuality, CSBD, and RSD highlights the need for an interdisciplinary approach combining pharmacological interventions with psychotherapy focused on emotional regulation, improvement of interpersonal relationships, and reduction of risky behaviors. Further research..."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry • Sexual Disorders

Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge-Eating Disorder: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. (PubMed, Eur Eat Disord Rev) - "LDX demonstrates significant efficacy in reducing binge-eating behaviours and associated obsessive-compulsive symptoms in patients with BED, with a tolerable safety profile. These findings support the clinical use of LDX for managing BED."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Binge Eating Disorder • CNS Disorders • Depression • Genetic Disorders • Mood Disorders • Obesity • Psychiatry

Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users (clinicaltrials.gov) - P2 | N=440 | Recruiting | Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Trial completion date: Nov 2025 ➔ Apr 2028 | Trial primary completion date: Nov 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry

Insomnia is associated with psychological distress in individuals with methamphetamine dependence. (PubMed, Australas Psychiatry) - "This study examined the relationship between insomnia severity and psychological distress in treatment-seeking individuals with methamphetamine dependence.MethodsThis is a secondary cross-sectional analysis of baseline data from 152 participants enrolled in a randomised controlled trial of lisdexamfetamine versus placebo for methamphetamine dependence. In adjusted models, insomnia remained associated with distress: each 1-point ISI increase related to a 2.1-2.5% rise in DASS-21 depression and stress scores (β = 0.021-0.025, p = .003-.007), and a 6.5% increase in total scores (β = 0.063, p < .001); the association with anxiety was attenuated.ConclusionsOur study identified insomnia as an independent correlate of psychological distress in treatment-seeking individuals with methamphetamine dependence. Findings underscore sleep problems' relevance and support further research into sleep-focused interventions."

Journal • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Pharmacological management of binge eating disorder. (PubMed, Ment Health Clin) - "Treatment guidelines for binge eating disorder (BED) lack substantial recommendations for specific pharmacological management beyond lisdexamfetamine. This may lead clinicians to question what other options are available for managing BED. The following clinical scenarios will review existing data examining the use of several pharmacological agents for BED, including stimulants, glucagon-like peptide-1 agonists, naltrexone, antidepressants, and antiseizure medications."

Journal • Binge Eating Disorder • CNS Disorders • Epilepsy

Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: University of Minnesota | Trial completion date: Nov 2029 ➔ Jul 2027 | Trial primary completion date: Nov 2028 ➔ Jul 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof). (PubMed, CNS Drugs) - "Among 24 distinct compounds studied, only 1 agent, lisdexamfetamine dimesylate, received approval from the U.S. Food and Drug Administration (FDA) for an ED during this period...While some emerging agents show promise, such as solriamfetol and psilocybin, there remains a significant lack of evidence-based pharmacological interventions for anorexia nervosa and a dearth of progress in pharmacotherapy for bulimia nervosa. Overall, the past 15 years have witnessed limited advancements in pharmacotherapy for EDs. There remains an urgent need for rigorous clinical trials in this area in addition to increased prioritization of ED research at the public health level to overcome longstanding barriers in the treatment of EDs."

Journal • Review • Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders • Psychiatry

Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings. (PubMed, BMJ Open) - P4 | "Findings will be presented such that individual participants will not be identifiable. ACTRN12624001061527."

Clinical protocol • Journal • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD. (PubMed, Front Psychiatry) - P=N/A | "Findings suggest that guanfacine, unlike lisdexamfetamine, may not improve attention in children and adolescents with ADHD. https://clinicaltrials.gov/study/NCT03333668?term=NCT03333668&rank=1#study-plan, identifier NCT03333668."

Journal • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Psychiatry

Lisdexamfetamine-Induced Angioedema and Leukocytoclastic Vasculitis: A Case Report. (PubMed, Australas J Dermatol) - "A positive rechallenge after an extensive workup confirmed a drug-induced reaction. This case highlights lisdexamfetamine as a cause of non-allergic angioedema and leukocytoclastic vasculitis, and demonstrates the diagnostic value of a medication history and rechallenge."

Journal • ADHD (Impulsive Aggression) • Alpha-1 Antitrypsin Deficiency • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Immunology • Psychiatry • Pulmonary Disease • Respiratory Diseases • Vasculitis

Raynaud's phenomenon during treatment with lisdexamfetamine: risk of cerebral vasospasm? (PubMed, Einstein (Sao Paulo)) - "Lisdexamfetamine, a prodrug used to treat Attention Deficit/Hyperactivity Disorder in children, adolescents, and adults, is an inactive substance that is converted into its active form (dextroamphetamine) after being metabolized. In both patients presented in this report, discontinuation of the medication led to resolution of the phenomenon within a few days. This report highlights the fact that one of the patients reported episodes of dizziness during Raynaud's phenomenon, drawing attention to the potential associated complications."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Psychiatry • Rheumatology

Involvement of the histaminergic system on maladaptive feeding behavior in an animal model of binge eating in female rats (Neuroscience 2025) - "To date, lisdexamfetamine dimesylate remains the only FDA-approved pharmacotherapy for BED, highlighting the urgent need for novel therapeutic approaches...Notably, pharmacological enhancement of HA transmission, both acutely and chronically, effectively suppressed binge-like behavior and prevented several of the associated molecular alterations. These findings suggest a potential involvement of the HA system in the pathophysiology of binge eating and support its consideration as a novel pharmacological target for BED treatment."

Preclinical • Binge Eating Disorder • CNS Disorders

Exposures to attention deficient hyperactivity disorder medications reported to the New South Wales Poisons Information Centre (2014-2023): A retrospective study. (PubMed, Aust N Z J Psychiatry) - "Exposures to attention deficit hyperactivity disorder medications present a growing public health issue. Rates have risen annually over the past decade, and the majority require medical attention, placing strain on healthcare resources. There are notable differences in exposure patterns among affected age groups. This highlights the need for targeted preventive measures focused on both quality use of the medication being prescribed as well as considering the circumstances and safety of the individual and household."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Disparities in Obesity Medication Dispensing Among Adolescents in Real-World Settings (OBESITY WEEK 2025) - "We included commonly prescribed OMs in our healthcare system, including Semaglutide, Liraglutide, Tirzepatide, Phentermine, Topiramate, Phentermine-Topiramate, Metformin, and Lisdexamfetamine... This is the first study to examine the likelihood of OM dispensing in a pediatric population. We identified stark disparities in whether an OM was dispensed by insurance, sex, and obesity severity—particularly for newer GLP-1 receptor agonists. As OM use continues to rise among youth, these gaps may widen without intentional intervention."

Clinical • Real-world • Real-world evidence • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics

Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. (PubMed, Br J Psychiatry) - "ADHD medication use during pregnancy is associated with increased miscarriage risk. However, filled prescriptions may not reflect actual use. Further research is needed to clarify these associations and refine risk estimates."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPER. (PubMed, Trials) - "Given that untreated ADHD is associated with poor clinical outcomes, unemployment and criminal justice system involvement, clear evidence in this area is likely to improve recovery for individuals with ADHD and a history of SMI, reducing costs for the individual, the NHS and society."

HEOR • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Mood Disorders • Psychiatry

Prescription Stimulants Can Increase Risk of Arrhythmias: Systematic Review and Meta-Analysis (AHA 2025) - "These agents, including amphetamines, methylphenidate, modafinil, and lisdexamfetamine, elevate sympathetic tone and may precipitate cardiac arrhythmias, including atrial fibrillation (AF) and ventricular tachyarrhythmias. All major stimulant subclasses were significantly associated with increased arrhythmia risk, with the highest risk observed in amphetamines. These findings emphasize the potential cardiovascular consequences of stimulant therapy and reinforce the need for ongoing cardiac monitoring. Further research is warranted to delineate the safety profiles of individual stimulant medications."

Retrospective data • Review • ADHD (Impulsive Aggression) • Atrial Fibrillation • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Narcolepsy • Psychiatry • Sleep Disorder • Ventricular Tachycardia